Redox Proteins and Radiotherapy

Clinical Oncology

Volumn 26, Issue 5, 2014, Pages 289-300

  Zhang, Y ^a   Martin, S G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Radiosensitivity; Radiotherapy; Reactive oxygen species; Redox homeostasis; Redox imaging; Redox proteins

Indexed keywords

ANTIOXIDANT; FREE RADICAL; GLUTAREDOXIN; GLUTATHIONE; PEROXIREDOXIN; PROTEIN; REACTIVE OXYGEN METABOLITE; REDOX PROTEIN; SUPEROXIDE DISMUTASE; THIOREDOXIN; UNCLASSIFIED DRUG; RADIOSENSITIZING AGENT;

ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CYTOTOXICITY; DNA DAMAGE; HOMEOSTASIS; HUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOSENSITIVITY; TUMOR CELL; DIET SUPPLEMENTATION; DRUG EFFECTS; METABOLISM; NEOPLASMS; OXIDATION REDUCTION REACTION; PHYSIOLOGY; RADIATION DOSE; SIGNAL TRANSDUCTION;

ANTIOXIDANTS; DIETARY SUPPLEMENTS; FREE RADICALS; GLUTAREDOXINS; GLUTATHIONE; HOMEOSTASIS; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; PEROXIREDOXINS; PROGNOSIS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; THIOREDOXINS;

EID: 84898040885     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.02.003     Document Type: Article

References (127)

1. Betteridge D.J. What is oxidative stress?. Metabolism 2000, 49:3-8.
2. Hall E.J., Giaccia A.J. Radiobiology for the radiologist 2012, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia. 7th ed.
3. D'Errico M., Parlanti E., Dogliotti E. Mechanism of oxidative DNA damage repair and relevance to human pathology. Mutat Res 2008, 659:4-14.
4. Evans M.D., Dizdaroglu M., Cooke M.S. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res 2004, 567:1-61.
5. Cadet J., Douki T., Ravanat J.L. Oxidatively generated base damage to cellular DNA. Free Radic Biol Med 2010, 49:9-21.
6. Finkel T. Signal transduction by reactive oxygen species. JCell Biol 2011, 194:7-15.
7. Kovacic P., Jacintho J.D. Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr Med Chem 2001, 8:773-796.
8. Tew K.D., Townsend D.M. Redox platforms in cancer drug discovery and development. Curr Opin Chem Biol 2011, 15:156-161.
9. Giles G.I. The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 2006, 12:4427-4443.
10. McCord J.M., Keele B.B., Fridovich I. An enzyme-based theory of obligate anaerobiosis: the physiological function of superoxide dismutase. Proc Natl Acad Sci USA 1971, 68:1024-1027.
11. Wu W.S. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006, 25:695-705.
12. Thomas E.L., Milligan T.W., Joyner R.E., Jefferson M.M. Antibacterial activity of hydrogen peroxide and the lactoperoxidase-hydrogen peroxide-thiocyanate system against oral streptococci. Infect Immun 1994, 62:529-535.
13. Lu G., Greene E.L., Nagai T., Egan B.M. Reactive oxygen species are critical in the oleic acid-mediated mitogenic signaling pathway in vascular smooth muscle cells. Hypertension 1998, 32:1003-1010.
14. Siems W.G., Grune T., Esterbauer H. 4-Hydroxynonenal formation during ischemia and reperfusion of rat small intestine. Life Sci 1995, 57:785-789.
15. Weydert C.J., Cullen J.J. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protoc 2010, 5:51-66.
16. Fattman C.L., Schaefer L.M., Oury T.D. Extracellular superoxide dismutase in biology and medicine. Free Radic Biol Med 2003, 35:236-256.
17. Chelikani P., Fita I., Loewen P.C. Diversity of structures and properties among catalases. Cell Mol Life Sci 2004, 61:192-208.
18. Liu J.R., Hinkhouse M.M., Sun W.Q., et al. Redox regulation of pancreatic cancer cell growth: role of glutathione peroxidase in the suppression of the malignant phenotype. Hum Gene Ther 2004, 15:239-250.
19. Wood Z.A., Poole L.B., Karplus P.A. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 2003, 300:650-653.
20. Tavender T.J., Sheppard A.M., Bulleid N.J. Peroxiredoxin IV is an endoplasmic reticulum-localized enzyme forming oligomeric complexes in human cells. Biochem J 2008, 411:191-199.
21. Nguyen-nhu N.T., Berck J., Clippe A., et al. Human peroxiredoxin 5 gene organization, initial characterization of its promoter and identification of alternative forms of mRNA. Biochim Biophys Acta 2007, 1769:472-483.
22. Ho Y.S., Magnenat J.L., Bronson R.T., et al. Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia. JBiol Chem 1997, 272:16644-16651.
23. Esworthy R.S., Aranda R., Martin M.G., Doroshow J.H., Binder S.W., Chu F.F. Mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol Gastrointest Liver Physiol 2001, 281:G848-G855.
24. Watson W.H., Chen Y., Jones D.P. Redox state of glutathione and thioredoxin in differentiation and apoptosis (Reprinted from Thiol Metabolism and Redox Regulation of Cellular Functions). Biofactors 2003, 17:307-314.
25. Meister A. Glutathione-ascorbic acid antioxidant system in animals. JBiol Chem 1994, 269:9397-9400.
26. Montero A.J., Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011, 71:1385-1396.
27. Chai Y.C., Ashraf S.S., Rokutan K., Johnston R.B., Thomas J.A. S-thiolation of individual human neutrophil proteins including actin by stimulation of the respiratory burst: evidence against a role for glutathione disulfide. Arch Biochem Biophys 1994, 310:273-281.
28. Powis G., Mustacich D., Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000, 29:312-322.
29. Powis G., Montfort W.R. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 2001, 41:261-295.
30. Gasdaska J.R., Berggren M., Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ 1995, 6:1643-1650.
31. Gladyshev V.N., Jeang K.T., Stadtman T.C. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci USA 1996, 93:6146-6151.
32. Mustacich D., Powis G. Thioredoxin reductase. Biochem J 2000, 346:1-8.
33. Nishiyama A., Matsui M., Iwata S., et al. Identification of thioredoxin-binding protein-2/vitamin D-3 up-regulated protein 1 as a negative regulator of thioredoxin function and expression. JBiol Chem 1999, 274:21645-21650.
34. Yamanaka H., Maehira F., Oshiro M., et al. Apossible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast two-hybrid system. Biochem Biophys Res Commun 2000, 271:796-800.
35. Junn E., Han S.H., Im J.Y., et al. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 2000, 164(12):6287-6295.
36. Fernandes A.P., Fladvad M., Berndt C., et al. Anovel monothiol glutaredoxin (Grx4) from Escherichia coli can serve as a substrate for thioredoxin reductase. JBiol Chem 2005, 280:24544-24552.
37. Herrero E., Belli G., Casa C. Structural and functional diversity of glutaredoxins in yeast. Curr Protein Pept Sci 2010, 659-668.
38. Eklund H., Cambillau C., Sjoberg B.M., et al. Conformational and functional similarities between glutaredoxin and thioredoxins. EMBO J 1984, 3:1443-1449.
39. Lillig C.H., Berndt C., Holmgren A. Glutaredoxin systems. Biochim Biophys Acta 2008, 1780:1304-1317.
40. Johansson C., Lillig C.H., Holmgren A. Human mitochondrial glutaredoxin reduces S-glutathionylated proteins with high affinity accepting electrons from either glutathione or thioredoxin reductase. JBiol Chem 2004, 279:7537-7543.
41. Lillig C.H., Berndt C., Vergnolle O., et al. Characterization of human glutaredoxin 2 as iron-sulfur protein: a possible role as redox sensor. Proc Natl Acad Sci USA 2005, 102:8168-8173.
42. Witte S., Villalba M., Bi K., Liu Y., Isakov N., Altman A. Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by PICOT, a novel protein kinase C-interacting protein with a thioredoxin homology domain. JBiol Chem 2000, 275:1902-1909.
43. LaVerne J.A. Track effects of heavy ions in liquid water. Radiat Res 2000, 153:487-496.
44. Meesungnoen J., Jay-Gerin J.P. High-LET radiolysis of liquid water with 1H+, 4He2+, 12C6+, and 20Ne9+ ions: effects of multiple ionization. JPhys Chem A 2005, 109:6406-6419.
45. Munro T.R. The relative radiosensitivity of the nucleus and cytoplasm of Chinese hamster. Radiat Res 1970, 42:451-470.
46. Totter J.R. Spontaneous cancer and its possible relationship to oxygen metabolism. Proc Natl Acad Sci USA 1980, 77:1763-1767.
47. Demple B., Harrison L. Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem 1994, 63:915-948.
48. Gros L., Saparbaev M.K., Laval J. Enzymology of the repair of free radicals-induced DNA damage. Oncogene 2002, 21:8905-8925.
49. Storr S.J., Woolston C.M., Martin S.G. Base excision repair, the redox environment and therapeutic implications. Curr Mol Pharmacol 2012, 5:88-101.
50. Storr S.J., Woolston C.M., Zhang Y., Martin S.G. Redox environment, free radical, and oxidative DNA damage. Antioxid Redox Signal 2013, 18:2399-2408.
51. Dethmers J.K., Meister A. Glutathione export by human lymphoid cells: depletion of glutathione by inhibition of its synthesis decreases export and increases sensitivity to irradiation. Proc Natl Acad Sci USA 1981, 78:7492-7496.
52. Williamson J.M., Boettcher B., Meister A. Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis. Proc Natl Acad Sci USA 1982, 79:6246-6249.
53. Mitchell J.B., Russo A., Biaglow J.E., McPherson S. Cellular glutathione depletion by diethyl maleate or buthionine sulfoximine: no effect of glutathione depletion on the oxygen enhancement ratio. Radiat Res 1983, 96:422-428.
54. Clark E.P., Epp E.R., Morse-Gaudio M., Biaglow J.E. The role of glutathione in the aerobic radioresponse. I. Sensitization and recovery in the absence of intracellular glutathione. Radiat Res 1986, 108:238-250.
55. Biaglow J.E., Clark E.P., Epp E.R., Morse-Guadio M., Varnes M.E., Mitchell J.B. Nonprotein thiols and the radiation response of A549 human lung carcinoma cells. Int J Radiat Biol Relat Stud Phys Chem Med 1983, 44:489-495.
56. Boivin A., Hanot M., Malesys C., et al. Transient alteration of cellular redox buffering before irradiation triggers apoptosis in head and neck carcinoma stem and non-stem cells. PLoS One 2011, 6:e14558.
57. Bump E.A., Yu N.Y., Brown J.M. Radiosensitization of hypoxic tumor cells by depletion of intracellular glutathione. Science 1982, 217:544-545.
58. Russo A., Mitchell J.B. Radiation response of Chinese hamster cells after elevation of intracellular glutathione levels. Int J Radiat Oncol Biol Phys 1984, 10:1243-1247.
59. Pankiv S., Moller S., Bjorkoy G., Moens U., Huseby N.E. Radiation-induced upregulation of gamma-glutamyltransferase in colon carcinoma cells is mediated through the Ras signal transduction pathway. Biochim Biophys Acta 2006, 1760:151-157.
60. Koch C.J., Stobbe C.C., Baer K.A. Combined radiation-protective and radiation-sensitizing agents. III: radiosensitization by misonidazole as a function of concentrations of endogenous glutathione or exogenous thiols. Int J Radiat Oncol Biol Phys 1986, 12:1151-1155.
61. Zhao Y., Seefeldt T., Chen W., et al. Increase in thiol oxidative stress via glutathione reductase inhibition as a novel approach to enhance cancer sensitivity to X-ray irradiation. Free Radic Biol Med 2009, 47:176-183.
62. Khil M.S., Kim S.H., Pinto J.T., Kim J.H. Ethacrynic acid: a novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys 1996, 34:375-380.
63. Smart D.D.K., Ortiz K.L., Mattson D., et al. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res 2004, 64:6716-6724.
64. Demizu Y., Sasaki R., Trachootham D., et al. Alterations of cellular redox state during NNK-induced malignant transformation and resistance to radiation. Antioxid Redox Signal 2008, 10:951-961.
65. Selenius M., Hedman M., Brodin D., et al. Effects of redox modulation by inhibition of thioredoxin reductase on radiosensitivity and gene expression. JCell Mol Med 2012, 16:1593-1605.
66. Tuttle S., Hertan L., Daurio N., et al. The chemopreventive and clinically used agent curcumin sensitizes HPV (-) but not HPV (+) HNSCC to ionizing radiation, invitro and in a mouse orthotopic model. Cancer Biol Ther 2012, 13:575-584.
67. Mehta M.P., Shapiro W.R., Phan S.C., et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009, 73:1069-1076.
68. Yamaguchi F., Takata M., Kamitori K., et al. Rare sugar D-allose induces specific up-regulation of TXNIP and subsequent G1 cell cycle arrest in hepatocellular carcinoma cells by stabilization of p27kip1. Int J Oncol 2008, 32:377-385.
69. Hoshikawa H., Indo K., Mori T., Mori N. Enhancement of the radiation effects by D-allose in head and neck cancer cells. Cancer Lett 2011, 306:60-66.
70. Wang T.L., Tamae D., LeBon T., Shively J.E., Yen Y., Li J.J. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res 2005, 65:10338-10346.
71. Lee Y.S., Chang H.W., Jeong J.E., Lee S.W., Kim S.Y. Proteomic analysis of two head and neck cancer cell lines presenting different radiation sensitivity. Acta Otolaryngol 2008, 128:86-92.
72. Park J.J., Chang H.W., Jeong E.J., et al. Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2009, 73:1196-1202.
73. Chen W.C., McBride W.H., Iwamoto K.S., et al. Induction of radioprotective peroxiredoxin-I by ionizing irradiation. JNeurosci Res 2002, 70:794-798.
74. Zhang B., Su Y.P., Ai G.P., Wang Y., Wang T., Wang F.C. Involvement of peroxiredoxin I in protecting cells from radiation-induced death. JRadiat Res 2005, 46:305-312.
75. Park S.H., Chung Y.M., Lee Y.S., et al. Antisense of human peroxiredoxin II enhances radiation-induced cell death. Clin Cancer Res 2000, 6:4915-4920.
76. Zhang B., Wang Y., Liu K.Y., et al. Adenovirus-mediated transfer of siRNA against peroxiredoxin I enhances the radiosensitivity of human intestinal cancer. Biochem Pharmacol 2008, 75:660-667.
77. Smith-Pearson P.S., Kooshki M., Spitz D.R., Poole L.B., Zhao W., Robbins M.E. Decreasing peroxiredoxin II expression decreases glutathione, alters cell cycle distribution, and sensitizes glioma cells to ionizing radiation and H(2)O(2). Free Radic Biol Med 2008, 45:1178-1189.
78. Brown C.O., Salem K., Wagner B.A., et al. Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase. Biochem J 2012, 444:515-527.
79. Murley J.S., Nantajit D., Baker K.L., Kataoka Y., Li J.J., Grdina D.J. Maintenance of manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by repeated administration of the free thiol form of amifostine. Radiat Res 2008, 169:495-505.
80. Gao Z., Sarsour E.H., Kalen A.L., Li L., Kumar M.G., Goswami P.C. Late ROS accumulation and radiosensitivity in SOD1-overexpressing human glioma cells. Free Radic Biol Med 2008, 45:1501-1509.
81. Xu Y., Fang F., St Clair D.K., et al. Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther 2007, 6:2048-2056.
82. Guo H., Seixas-Silva J.A., Epperly M.W., et al. Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (SOD2) transgene. Radiat Res 2003, 159:361-370.
83. Hahn S.M., Tochner Z., Krishna C.M., et al. Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res 1992, 52:1750-1753.
84. Cuscela D., Coffin D., Lupton G.P., et al. Protection from radiation-induced alopecia with topical application of nitroxides: fractionated studies. Cancer J Sci Am 1996, 2:273-278.
85. Hahn S.M., Sullivan F.J., DeLuca A.M., et al. Evaluation of tempol radioprotection in a murine tumor model. Free Radic Biol Med 1997, 22:1211-1216.
86. Woolston C.M., Al-Attar A., Storr S.J., Ellis I.O., Morgan D.A., Martin S.G. Redox protein expression predicts radiotherapeutic response in early-stage invasive breast cancer patients. Int J Radiat Oncol Biol Phys 2011, 79:1532-1540.
87. Schumaker L., Nikitakis N., Goloubeva O., Tan M., Taylor R., Cullen K.J. Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone. Clin Cancer Res 2008, 14:5877-5883.
88. Silvestrini R., Veneroni S., Benini E., et al. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. JNatl Cancer Inst 1997, 89:639-645.
89. Woolston C.M., Storr S.J., Ellis I.O., Morgan D.A.L., Martin S.G. Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer. Radiother Oncol 2011, 100:308-313.
90. Yanagawa T., Omura K., Harada H., et al. Peroxiredoxin I expression in tongue squamous cell carcinomas as involved in tumor recurrence. Int J Oral Maxillofac Surg 2005, 34:915-920.
91. Quan C., Cha E.J., Lee H.L., Han K.H., Lee K.M., Kim W.J. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. JUrol 2006, 175:1512-1516.
92. Karihtala P., Mantyniemi A., Kang S.W., Kinnula V.L., Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003, 9:3418-3424.
93. Averill-Bates D.A., Przybytkowski E. The role of glucose in cellular defences against cytotoxicity of hydrogen peroxide in Chinese hamster ovary cells. Arch Biochem Biophys 1994, 312:52-58.
94. Nath K.A., Ngo E.O., Hebbel R.P., Croatt A.J., Zhou B., Nutter L.M. alpha-Ketoacids scavenge H2O2 invitro and invivo and reduce menadione-induced DNA injury and cytotoxicity. Am J Physiol 1995, 268:C227-C236.
95. Sharma P.K., Varshney R. 2-Deoxy-D-glucose and 6-aminonicotinamide-mediated Nrf2 down regulation leads to radiosensitization of malignant cells via abrogation of GSH-mediated defense. Free Radic Res 2012, 46:1446-1457.
96. Sharma P.K., Bhardwaj R., Dwarakanath B.S., Varshney R. Metabolic oxidative stress induced by a combination of 2-DG and 6-AN enhances radiation damage selectively in malignant cells via non-coordinated expression of antioxidant enzymes. Cancer Lett 2010, 295:154-166.
97. Bhardwaj R., Sharma P.K., Jadon S.P., Varshney R. Acombination of 2-deoxy-D-glucose and 6-aminonicotinamide induces cell cycle arrest and apoptosis selectively in irradiated human malignant cells. Tumour Biol 2012, 33:1021-1030.
98. Sharma R.A., Euden S.A., Platton S.L., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10:6847-6854.
99. Lao C.D., Ruffin M.T., Normolle D., et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006, 6:10.
100. Rao C.V., Rivenson A., Simi B., Reddy B.S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995, 55:259-266.
101. Kawamori T., Lubet R., Steele V.E., et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999, 59:597-601.
102. Kuttan R., Sudheeran P.C., Josph C.D. Turmeric and curcumin as topical agents in cancer therapy. Tumori 1987, 73:29-31.
103. Goel A., Aggarwal B.B. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010, 62:919-930.
104. Hwang D.R., Wu Y.S., Chang C.W., et al. Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system. Bioorg Med Chem 2006, 14:83-91.
105. Sun Y., St Clair D.K., Xu Y., Crooks P.A., St Clair W.H. ANADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res 2010, 70:2880-2890.
106. Xu Y., Fang F., Miriyala S., et al. KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. Cancer Res 2013, 73:4406-4417.
107. Karthikeyan S., Kanimozhi G., Prasad N.R., Mahalakshmi R. Radiosensitizing effect of ferulic acid on human cervical carcinoma cells invitro. Toxicol InVitro 2011, 25:1366-1375.
108. Sun C., Zhang H., Ma X.F., et al. Isoliquiritigenin enhances radiosensitivity of HepG2 cells via disturbance of redox status. Cell Biochem Biophys 2013, 65:433-444.
109. Rao S.K., Rao P.S., Rao B.N. Preliminary investigation of the radiosensitizing activity of guduchi (Tinospora cordifolia) in tumor-bearing mice. Phytother Res 2008, 22:1482-1489.
110. Tak J.K., Lee J.H., Park J.W. Resveratrol and piperine enhance radiosensitivity of tumor cells. BMB Rep 2012, 45:242-246.
111. Yuan J., Lovejoy D.B., Richardson D.R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: invitro and invivo assessment. Blood 2004, 104:1450-1458.
112. Richardson D.R., Sharpe P.C., Lovejoy D.B., et al. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. JMed Chem 2006, 49:6510-6521.
113. Tian J., Peehl D.M., Zheng W., Knox S.J. Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status. Cancer Lett 2010, 298:231-237.
114. Tsuchida E., Komatsu T., Hamamatsu K., et al. Exchange transfusion with albumin-heme as an artificial O2-infusion into anesthetized rats: physiological responses, O2-delivery, and reduction of the oxidized hemin sites by red blood cells. Bioconjug Chem 2000, 11:46-50.
115. Horinouchi H., Yamamoto H., Komatsu T., Huang Y., Tsuchida E., Kobayashi K. Enhanced radiation response of a solid tumor with the artificial oxygen carrier 'albumin-heme'. Cancer Sci 2008, 99:1274-1278.
116. Ahmad J., Ahamed M., Akhtar M.J., et al. Apoptosis induction by silica nanoparticles mediated through reactive oxygen species in human liver cell line HepG2. Toxicol Appl Pharmacol 2012, 259:160-168.
117. Morishige T., Yoshioka Y., Inakura H., et al. The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1beta production, ROS production and endosomal rupture. Biomaterials 2010, 31:6833-6842.
118. Klein S., Dell'Arciprete M.L., Wegmann M., et al. Oxidized silicon nanoparticles for radiosensitization of cancer and tissue cells. Biochem Biophys Res Commun 2013, 434:217-222.
119. Cook J.A., Gius D., Wink D.A., Krishna M.C., Russo A., Mitchell J.B. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 2004, 14:259-266.
120. Hyodo F., Soule B.P., Matsumoto K., et al. Assessment of tissue redox status using metabolic responsive contrast agents and magnetic resonance imaging. JPharm Pharmacol 2008, 60:1049-1060.
121. Hyodo F., Matsumoto K., Matsumoto A., Mitchell J.B., Krishna M.C. Probing the intracellular redox status of tumors with magnetic resonance imaging and redox-sensitive contrast agents. Cancer Res 2006, 66:9921-9928.
122. Matsumoto K., Hyodo F., Matsumoto A., et al. High-resolution mapping of tumor redox status by magnetic resonance imaging using nitroxides as redox-sensitive contrast agents. Clin Cancer Res 2006, 12:2455-2462.
123. Davis R.M., Sowers A.L., DeGraff W., et al. Anovel nitroxide is an effective brain redox imaging contrast agent and invivo radioprotector. Free Radic Biol Med 2011, 51:780-790.
124. Davis R.M., Matsumoto S., Bernardo M., et al. Magnetic resonance imaging of organic contrast agents in mice: capturing the whole-body redox landscape. Free Radic Biol Med 2011, 50:459-468.
125. Jagadish B., Guntle G.P., Zhao D., et al. Redox-active magnetic resonance imaging contrast agents: studies with thiol-bearing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid derivatives. JMed Chem 2012, 55:10378-10386.
126. Zhelev Z., Bakalova R., Aoki I., Lazarova D., Saga T. Imaging of superoxide generation in the dopaminergic area of the brain in Parkinson's disease, using mito-TEMPO. ACS Chem Neurosci 2013, 4(11):1439-1445.
127. Ishihara Y., Itoh K., Mitsuda Y., et al. Involvement of brain oxidation in the cognitive impairment in a triple transgenic mouse model of Alzheimer's disease: noninvasive measurement of the brain redox state by magnetic resonance imaging. Free Radic Res 2013, 47:731-739.